To evaluate the effect of intravitreal bevacizumab, macular grid laser and both in combination in patients of clinically significant macular edema

To compare the efficacy between intravitreal bevacizumab, macular grid photocoagulation and both in combination for the treatment of clinically significant macular edema.

21 cases of clinically significant macular edema were prospectively divided in three groups randomly. In group A, patients received bevacizumab 0.05ml intravitreally. In group B, patients received macular grid photocoagulation. In group C, patients received combination of macular grid photocoagulation and bevacizumab 0.05ml intravitreally. Central macular thickness and best corrected visual acuity were the main outcomes measured.

The difference in central macular thickness and best corrected visual acuity among the groups at baseline was not statistically significant (p>0.05). There was significantly more improvement in central macular thickness and best corrected visual acuity in group C than in group A and group B at two months follow-up (p<0.05).

The better short term therapeutic outcomes in the group C indicates that combining intravitreal bevacizumab and macular grid photocoagulation might be more effective than intravitreal bevacizumab and macular grid photocoagulation alone for the treatment of clinically significant macular edema.